Agios Pharma Stock Climbs On Royalty Pharma's Deal To Buy Royalty Stake In Vorasidenib

Royalty Pharma plc (RPRX) announced Tuesday that it has acquired an interest in Agios Pharmaceuticals' (AGIO) royalty on Servier's vorasidenib for $905 million in upfront cash.

Related Keywords

Pablo Legorreta ,More Such Health News ,Drug Administration ,Nasdaq ,Goodwin Procter ,Fenwick West ,Royalty Pharma ,Agios Pharmaceutical ,Agios Pharma ,Breakthrough Therapy Designation ,Prescription Drug User Fee Act ,Chief Executive Officer ,